Jun 08, 2022 / 06:30PM GMT
Maurice Thomas Raycroft - Jefferies LLC, Research Division - Equity Analyst
My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'm happy to introduce our guest today, Emil Kakkis, the CEO of Ultragenyx. Thanks a lot for joining us today, Emil.
Emil D. Kakkis - Ultragenyx Pharmaceutical Inc. - President, CEO & Director
Thanks for having me, Maury.
Maurice Thomas Raycroft - Jefferies LLC, Research Division - Equity Analyst
And we're going to do a fireside chat discussion. So for those who may be new to the story, can you provide a 1-minute overview of Ultragenyx, your commercial products and your pipeline?
Emil D. Kakkis - Ultragenyx Pharmaceutical Inc. - President, CEO & Director
Yes. Ultragenyx is a rare -- a company focused on rare and ultra-rare disease, has been in business 12 years. We're a commercial company with 4 approved products that we're commercializing in the U.S., Canada, Latin America, Europe and, most recently, beginning in
Ultragenyx Pharmaceutical Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers